Topotecan ([s]-9-dimethylaminomethyl-10-hydroxy-camptothecin) is a semisynthetic water-soluble analog of the plant alkaloid camptothecin and has exhibited antitumor activity in experimental tumor models.
xypropyl]indolizino [1,2-b] quinoline-1-(11-H)-one (camptothecin-21-isopropylamide) was synthesized by the method of Adamovics et al. 9) b-D-Galactosidase (b-Gal; EC 3.2.1.23) from Escherichia coli and 4-methylumbelliferyl-b-D-galactopyranoside were obtained from Boehringer Mannheim (Mannheim, Germany). N-(4-Aminophenyl)maleimide (APM) was purchased from Tokyo Kasei Kogyo Co., Ltd. (Tokyo, Japan).
Preparation of the Immunogen for Topotecan
The reactions involved in the preparative process used in the present study are shown in Fig. 2 . m-Aminobenzoic acid (m-ABA) (2 mg, 14.5 mmol) in 200 ml 2 N hydrochloric acid was diazotized with sodium nitrite (2 mg, 29 mmol) in 50 ml distilled water at 0°C for 10 min. Next, 190 ml portions of the above reaction mixture containing diazotized m-ABA (ca. 11 mmol) was added directly to topotecan (5 mg, 11 mmol) in 10 ml of 0.5 M phosphate buffer (pH 7.5), followed by incubation at room temperature for 30 min with vigorous stirring. The solvent was mixed with 10 ml each of ethyl acetate and 0.33 M citric acid. The mixture was shaken vigorously, and the ethyl acetate layer containing topotecan-m-ABA was separated. The ethyl acetate layer was washed with saturated sodium chloride and drying over anhydrous sodium sulfate. The resulting topotecan-m-ABA was used without further purification for preparation of the conjugates using bovine serum albumin (BSA) as the topotecan immunogen. The yield of topotecan-m-ABA was tentatively estimated to be 52.0% according to HPLC measurements of the quantity of non-reacted topotecan. The molar extinction coefficients of topotecan-m-ABA were thus estimated to be 8200 at 280 nm and 16100 at 380 nm, representing those needed to evaluate the quantity of topotecan conjugated per mole of BSA.
1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDPC) (2.3 mg, 12 mmol) and N-hydroxysuccinimide (1.4 mg, 12 mmol) were added to a solution of topotecan-m-ABA (approximately 6 mmol) in 1 ml of 95% dioxane, and the resulting solution was allowed to stand at room temperature for 2 h. The reaction mixture was extracted with ethyl acetate, washed with water, dried over anhydrous sodium sulfate, and evaporated. The resulting residue in 100 ml N,N-dimethylformamide (DMF) was immediately mixed with BSA (10 mg) in 1 ml of 0.1 M phosphate buffer (pH 7.0), and incubated at 30°C for 3 h with stirring. The reaction mixture was chromatographed on a Sephadex G-100 column (2.8ϫ42 cm) with 0.1 M phosphate buffer (pH 7.0) containing 3 M urea. Then, the purified conjugate was examined spectrophotometrically, and was estimated to contain approximately 6.0 molecules of topotecan per BSA molecule, assuming the molar extinction coefficient of BSA was 43600 at 280 nm and those of topotecan-m-ABA were as described above. In addition, the pH of the conjugate solution was adjusted with phosphoric acid to 4.0 to convert the carboxylate form into the lactone form.
Preparation of Topotecan Antibody An aliquot containing 1 mg topotecan-BSA complex was emulsified with an equal volume of Freund's complete adjuvant. Two white female rabbits were each given multiple S.C. injections over sites along both sides of their backs. Booster injections were then given three times at bi-weekly intervals, using one-half the amount of the dose of the first immunization. The rabbits were bled from an ear vein 10 weeks after immunization began. The sera (10 ml) were separated by centrifugation and heated at 55°C for 30 min. Fractions of IgG were extracted from the sera with 50% saturated ammonium sulfate and chromatographed on a column of DEAE-Sephacel (2.1ϫ23 cm) using 17.5 mM phosphate buffer (pH 6.8) as an eluant. 10) The fraction passed through the column was lyophilized and used as anti-topotecan IgG for ELISA.
Preparation of the Topotecan-b b-Gal Conjugate Topotecan was labeled by binding to b-Gal, essentially by the same principle used for the previous preparation of irinotecan immunogen, using a cross-linker N-(4-diazophenyl) maleimide (DPM).
11) APM (1 mg, 5.3 mmol) in 20 ml DMF was acidified by the addition of 50 ml of 1 N acetic acid and then diazotized with sodium nitrite (0.75 mg, 10.9 mmol) in 50 ml distilled water at 0°C for 10 min. Next, 50 ml portions of the above reaction mixture containing DPM (ca. 2.2 mmol) was added directly to topotecan (1 mg, 2.2 mmol) in a mixed solution comprising 100 ml of DMF and 1 ml of 0.5 M phosphate buffer (pH 7.5), followed by incubation at room temperature for 15 min with vigorous stirring. The solvent was mixed with 2 ml each of ethyl acetate and 0.33 M citric acid. The mixture was shaken vigorously, and the ethyl acetate layer containing topotecan-DPM was separated. Then, the ethyl acetate layer was washed with saturated sodium chloride and dried over anhydrous sodium sulfate. The resulting topotecan-DPM was used without further purification for the coupling reaction with b-Gal. The yield of topotecan-DPM was tentatively estimated to be 32% according to HPLC measurements of the quantity of non-reacted topotecan. Fifty microliters of DMF solution containing topotecan-DPM (approximately 35 mg, 56 nmol) was mixed with b-Gal (156 mg, 0.28 nmol) in 1 ml of 0.1 M phosphate buffer (pH 6.0), followed by 30 min incubation at room temperature. The mixture was chromatographed on a Sepharose 6B column (2.0ϫ35 cm) using 20 mM phosphate buffer (pH 6.0) containing 0.1 M NaCl, 1 mM MgCl 2 , 0.1% BSA and 0.1% NaN 3 to remove any remaining small molecular compounds. Four-milliliter fractions were collected, and fractions 10 to 13, representing the main peak of the pure enzyme activity, were chosen as a label in the ELISA.
ELISA for Determination of Topotecan ELISA is based on the principle of competition between enzyme-labeled and unlabeled drugs for an immobilized antibody, followed by measurement of the marker enzyme activity of the immunocomplex bound to the solid phase. Briefly, the well in microtiter plates (Nunc F Immunoplates I; Nunc, Reskilde, Denmark) were coated by loading 150 ml of anti-topotecan IgG (10 mg/ml) in 10 mM Tris-HCl buffer (pH 8.5) containing 10 mM NaCl and 10 mM NaN 3 and allowed to stand overnight at 4°C. After the plates had been washed twice with 0.5 M phosphate buffer (pH 7.0) containing 10 mM ethylenediaminetetraacetate, 10 mM NaN 3 and 0.1% BSA (buffer A), they were incubated with 200 ml of buffer A containing 2% BSA for 20 min at 37°C to prevent non-specific adsorption. The anti-topotecan IgG-coated wells were then filled with 50 ml of either topotecan-treated samples, or PBS as a control, followed immediately by 50 ml of the pooled topote- The activity of the enzyme conjugate bound to each well was then measured by the addition of 125 ml of 0.1 mM 4-methylumbelliferyl-b-D-galactopyranoside in buffer A, followed by incubation of the wells at 37°C for 90 min. The enzyme reaction was stopped by the addition of 75 ml of 0.5 M glycine NaOH buffer (pH 10.3) to each well, and the resulting 4-methylumbelliferone was measured by spectrofluorometry at wavelengths of 355 nm for excitation and 460 nm for emmission using a fluorescence microplate reader (Fluoroskan Ascent, Labsystems, Helsinki, Finland).
HPLC Method The HPLC system consisted of a Shimadzu Model LC-10AT liquid chromatograph equipped with a spectrophotometric detector SPD-10AV and a 4ϫ125 mm Lichrospher 100 RP-18 endcapped (5 mm) column (Merch, Darmstadt, Germany). The column was eluted with 75 mM potassium dihydrogen phosphate containing 0.2% (v/v) triethylamine (adjusted to pH 6.0 with phosphoric acid) and methanol (65 : 35, v/v) at a flow rate of 1 ml/min, and the eluate was monitored at 230 nm. The retention time and peak height were measured with a Shimadzu C-R7A chromatopac.
A 100 ml serum was mixed with 100 ml of cold acetonitrile (0°C). After vortex mixing for 10 s and centrifugation at 9500 g for 1 min, the clear supernatant was injected into the HPLC system. Pharmacokinetic Evaluation Two male Wistar rats weighing 250 g each were administered 1 mg/kg topotecan by i.v. bolus injection into the fermoral vein. Blood was obtained from the cervical vein before administration of the drug and at intervals thereafter, and the serum separated immediately after blood sampling by centrifugation for 1 min (9500 g, 4°C) to prevent the lactone ring from opening or closing. The serum was immediately diluted 1 : 1 (v/v) with cold buffer A (4°C) and stored at Ϫ80°C for at most 48 h until assayed for topotecan concentration. For the determination of the analyte as lactone form, sample preparation was performed on an ice-water bath. The serum was diluted with cold buffer A (4°C) to obtain topotecan concentrations appropriate for their measurement by ELISA as described above. The prepared samples were immediately measured by the ELISA. Serum half-lives were calculated using a non-linear least-squares regression program, MULTI.
12)

RESULTS
Stability of Topotecan and Its Carboxylate
The stability of the topotecan and its carboxylate (40 mg/ml) was tested in buffer system at different pH and temperatures (Fig. 3) . Topotecan was stable for at least 3 h at 4°C at pH 6.5 and 7.0 (peak heights were greater than 96.9% of the 0-time peak height). The carboxylate form was stable for at least 3 h at 4°C at pH 7.0 and 7.5 (peak heights were greater than 96.6% of the 0-time peak height). In addition, these compounds in the serum samples were stable at Ϫ80°C for at least 48 h after dilution with buffer A (1 : 1, v/v) (peak heights were greater than 97.1% of the 0-time peak height).
ELISA The optimal quantities and optimal incubation time for each reaction were established. The dose-response standard curves of topotecan obtained in the serum system are shown in Fig. 4 . The limits of topotecan detection by ELISA were between 16 pg and 50 ng/ml of topotecan. For practical purposes, the working range was arbitrarily set between 80 and 2000 pg/ml based on the precision and accuracy findings for the ELISA (Table 1) , which showed this developed ELISA to be a reproducible technique. Recoveries of four different levels of topotecan ranging from 80 pg to 10 ng/ml were satisfactory, 96.0 to 105.6% (nϭ5). The coefficients of variation for intra-and inter-assays between topotecan concentrations of 80 pg to 10 ng/ml at four different levels each were 4.6 to 14.8% and 2.9 to 15.7% (nϭ5 for each), respectively. Specificity The antibody specificity was determined by the displacement of bound topotecan-b-Gal by other similar compounds. Values of the cross-reactivity were defined as the ratio of each compound to topotecan in the concentrations required for 50% inhibition of topotecan-b-Gal binding to the antibody. The anti-topotecan antibody showed 105.9% cross-reaction with SN-38, 70.4% with camptothecin, 2.2% with the carboxylate form of topotecan and 0.25% with camptothecin-21-isopropylamide ( Table 2) .
Comparison of ELISA and HPLC The ELISA method was compared with an HPLC method by using specific quantities of the lactone form of topotecan in human serum. Ten samples of various concentrations of topotecan ranging from 10 to 80 mg/ml were incubated with human serum for 24 h at 25°C. The lactone form to carboxylate form concentration ratios ranged from about 0.1 to 0.5. The HPLC technique analyzed the 10 samples, showing a linear relationship between the peak height of the topotecan chromatogram and the injected topotecan dose. ELISA determination was carried out using these topotecan samples, properly diluted to the drugconcentration range detectable by ELISA. Figure 5 shows that there was a good correlation between the values determined by the two methods, and the plot was linear as predicted by the equation Yϭ1.03 XϪ0.59, where Y is the concentration value determined by HPLC analysis and X is that determined by ELISA; the correlation coefficient was 0.989 (nϭ10).
Quantification of Topotecan in Rat Serum by ELISA Two rats, each weighing 250 g, were administered 1 mg/kg topotecan by rapid i.v. injection into the femoral vein. Blood was obtained from the same femoral vein before administration of the drug and at different intervals thereafter, and the topotecan content in the serum was determined by this ELISA. The disappearance of topotecan immunoreactivity from the serum is shown in Fig. 6 , demonstrating that a topotecan dose of as little as 23 ng/ml could be quantitatively measured in rat serum by the ELISA. For 5 h after drug administration, the decline of topotecan in serum was well described by a biphasic pattern of pharmacokinetics, with an average serum a-half-life of 2.3 min and a serum b-half-life of 118.8 min calculated for the two rats, showing that the serum drug level initially declined very rapidly but gradually slowed after administration. Rat urine was also collected and Camptothecin-21-isopropylamide 0.25 assayed for topotecan by the ELISA. The 5 h urine samples from the two animals contained an average of 17.4% of the delivered dose.
DISCUSSION
In general, the antibody specificity on the hapten appears to be towards the group most removed from the region of conjugation to the carrier protein in the immunogen structure. 13, 14) Topotecan has an aromatic hydroxy group in a moiety most removed from its lactone moiety. Therefore, to produce the specific antibody against the lactone form, topotecan immunogen was prepared using diazotized m-ABA with two selective functional groups of diazo and carboxylic acid as a cross-linking agent. The azotized position in the topotecan structure has not been clearly identified, but is predicted possibly to be at the C-11 or C-12 position of the topotecan molecule, judging from the typical azo-coupling reaction of compounds possessing a phenol moiety. The synthesized topotecan-m-ABA was purified by extraction in acidic pH and then conjugated through its carboxyl group to amino groups of protein by the N-succinimidyl ester method. 15) The lactone ring of topotecan may be opening, since synthesis and purification of the conjugate are carried out at pH 7.0. Therefore, the pH of purified conjugate was adjusted to 4.0 to convert the carboxylate form into the lactone form. The topotecan-BSA conjugate, with 6.0 mol of topotecan per mol of BSA, induced the formation of a specific antiserum in each of two rabbits immunized.
Topotecan-b-Gal conjugate was also prepared by essentilly the same procedure, with DPM structurally different from m-ABA, to eliminate production of antibody binding to the cross-linkage region of b-Gal. The conjugate thus obtained was stable in eluted buffer (pH 6.0) at 4°C for more than 6 months during which no loss of enzyme or immuno activity was seen.
Under physiological conditions the lactone form of topotecan undergoes a rapid and reversible pH-dependent conversion to a carboxylate form.
5) Therefore, to develop the ELISA for the determination of the lactone form in plasma, it was necessary to find the condition that both the lactone and carboxylate forms were stable. As shown in Fig. 3 , these compounds were stable for at least 3 h at 4°C and pH 7.0. From these findings, the antigen-antibody reaction of this ELISA was performed under pH 7.0 condition at 4°C for 3 h. The ELISA for topotecan as a lactone form can detect as little as 80 pg/ml of the drug and is reproducible, as indicated by the overall mean coefficient of variation of 8.6% intraassays and inter-assays at four different levels of topotecan (Fig. 4 and Table 1 ). The standard curve in the serum system was essentially the same as that in the buffer system.
The specificity of this ELISA is shown in Fig. 5 and Table  2 . The cross-reactivities of anti-topotecan antibody with topotecan analogues were examined. The antibody showed high affinity for camptothecin and SN-38. However, the antibody showed very limited reactivity with the other topotecan analogues which opened the lactone ring of topotecan. These findings indicated that the antibody-recognition site was the lactone moiety of the topotecan molecule. Since the antibody recognizes the lactone moiety of topotecan, this ELISA appears to be highly specific against the lactone form. Pharmacokinetic studies of topotecan in humans have previously been reported using HPLC method. 5, 16) Rapid hydrolysis of topotecan lactone results in plasma carboxylate levels exceeding lactone levels as early as 45 min after the start of a 30 min infusion. 5) During the elimination phase in human plasma, the plasma concentration of the carboxylate form is approximately four fold the concentration of the lactone form. 5) Then, using the human serum sample which contains the lactone and carboxylate forms (the lactone to carboxylate concentration ratios ranged from about 0.1 to 0.5), the ELISA method was compared with the HPLC method using specific quantities of the lactone form. There was good correlation; the correlation coefficient was 0.989 between the two methods (Fig. 5) . This finding also supports the high specificity of the ELISA.
As a demonstration of the potential of the ELISA, a preliminary pharmacokinetic study of topotecan in rats was performed (Fig. 6) . A biphasic pharmacokinetic pattern was observed with a rapid initial clearance followed by a slower elimination phase. The rat serum half-life was calculated to be 2.3 min for the a-phase and 118.8 min for the b-phase. The excretion of topotecan in the urine (based on the total dose administered) was about 17.4% over 5 h as an average in two rats. The reason for the very rapid initial clearance may be due to a hydrolysis of topotecan lactone in rat serum, judging from the stability of topotecan in plasma.
7) The major metabolite of topotecan is its carboxylate form. Other some metabolites of topotecan have already been identified in human plasma and urine. 17, 18) However, the maximal concentrations of these metabolites detected in human plasma and urine were relatively low. 17, 18) Therefore, this ELISA may be specific and sensitive enough to quantify topotecan for pharmacokinetic studies in animals and human.
The ELISA presented here is sensitive, specific, reproducible, and adaptable enough for analyses of a large number of samples. The assay should be a valuable tool for use in clinical pharmacological studies.
